Glutamate receptor ionotropic NMDA subunit 1 (GRIN1) glycine co-agonist site (GRIN1)

The Glutamate receptor ionotropic NMDA subunit 1 (GRIN1), also known as GluN1, is an essential component of the N-methyl-D-aspartate (NMDA) receptor complex, a heterotetrameric ligand-gated ion channel critical for excitatory neurotransmission and synaptic plasticity in the central nervous system (UniProt: P35486). A unique feature of the NMDA receptor is its requirement for the simultaneous binding of two distinct agonists: glutamate at the GluN2 subunit and glycine (or D-serine) at the glycine co-agonist site located on the GluN1 subunit (PubMed: 15312400). This glycine site is a significant pharmacological target because it is often not fully saturated under physiological conditions, providing a window for therapeutic modulation (PubMed: 21496568). Dysfunction of this site is linked to the NMDA receptor hypofunction hypothesis of schizophrenia, where enhancing glycine site activity may alleviate cognitive and negative symptoms (PubMed: 17982250). Conversely, overactivation of NMDA receptors can lead to excitotoxicity, contributing to neurodegenerative conditions like Alzheimer's disease and acute injuries like stroke (PubMed: 12467592). Drugs such as D-cycloserine act as partial agonists at this site to enhance learning and memory, while various antagonists have been explored for their potential neuroprotective and analgesic properties (PubChem: CID 3130). The site's accessibility and its role as an obligatory co-factor make it a primary focus for developing treatments for neuropsychiatric disorders (PubMed: 21496568).

Other names

GluN1 glycine siteNMDA receptor subunit 1 glycine siteGlycine-B siteNMDAR1 glycine siteStrychnine-insensitive glycine site

Modulation of NMDA receptor channel opening frequency and duration by binding to the obligatory glycine co-agonist site on the GluN1 subunit, which is required for glutamate-mediated ion conduction (PubMed: 15312400).